Abstract:Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total number of people they afflict. For many patients, considerable barriers exist in terms of access to appropriate care, delayed diagnosis and limited or non-existing treatment options. Motivated by these challenges, the rare disease patient community has played a critical role, elevating the patient voice and mobilizing legislation to support the development of programs that address the needs of patients with rare diseases.The US Orphan Drug Act of 1983 served as a key milestone in this journey, providing a roadmap for other countries to introduce and implement similar orphan drug legislation; more recently, the European Union (EU) has gone further to encourage the widespread adoption and implementation of rare disease plans or strategies designed to more adequately address the comprehensive needs of patients with rare diseases. Despite these legislative efforts and the growing contributions of patient advocacy groups in moving forward implementation and adoption of rare disease programs, gaps still exist across the policy landscape for several countries. To gain deeper insights into the challenges and opportunities to address key needs of rare disease patients, it is critical to define the current status of rare disease legislation and policy across a geographically and economically diverse selection of countries. We analyzed the rare disease policy landscape across 11 countries: Germany, France, the United Kingdom, Canada, Bulgaria, Turkey, Argentina, Mexico, Brazil, China, and Taiwan. The status and implementation of policy was evaluated for each country in the context of key patient needs across 5 dimensions: improving coordination of care, diagnostic resources, access to treatments, patient awareness and support, and promoting innovative research. Our findings highlight the continuing role of the patient community in driving the establishment and adoption of legislation and programs to improve rare disease care. Further, we found that while national rare disease plans provide important guidance for improving care, implementation of plans is uneven across countries. More research is needed to demonstrate the effect of specific elements of rare disease plans on patient outcomes.

Lessons from the Rare Diseases Registry and Analytics Platform framework for development of a national rare diseases registry for India

Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research

Indian Rare Disease Stakeholder Mapping

National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap.

Rare genetic diseases in India: Steps toward a nationwide mission program

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Informing a national rare disease registry strategy in Australia: a mixed methods study

Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Construction and Application of National Rare Diseases Registry System of China

Barriers and facilitators to designing, maintaining, and utilizing rare disease patient registries: a scoping review protocol

The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes

Rare disease emerging as a global public health priority

Current status of research in rare genetic disorders and drug discovery in India

National Rare Diseases Registry System (NRDRS): China’s first nation-wide rare diseases demographic analyses

Recommendations for Improving the Quality of Rare Disease Registries

Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis

Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy

Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China

Review of 11 national policies for rare diseases in the context of key patient needs